ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Recent in vitro studies from Hiwase et al. have identified a similar mechanism for the combination of Nilotinib and Dasatinib in CML cells overexpressing the Abcb1 efflux protein [38].